Associated tags: Patient, Radiopharmaceutical, Full Life Christian Centre, Pharmaceutical industry, Therapy, GMP, Cancer, Good manufacturing practice
Locations: BELGIUM, EUROPE, CHINA, DETROIT, SHANGHAI, NEW JERSEY, VIVA, GERMANY, UNITED STATES
"The Nuclear Permit is a significant regulatory milestone towards the construction of our radioisotope facility, which is an integral part of Full-Life's strategy to build a fully-integrated radiopharmaceutical company," said Philippe van Put, General Manager of Full-Life Technology Europe.
Key Points:
- "The Nuclear Permit is a significant regulatory milestone towards the construction of our radioisotope facility, which is an integral part of Full-Life's strategy to build a fully-integrated radiopharmaceutical company," said Philippe van Put, General Manager of Full-Life Technology Europe.
- "Actinium-225 ("Ac-225") has emerged as a highly promising, alpha-emitter isotope for use in radiotherapeutics to treat cancer, but demand has outstripped supply.
- Central to this collaborative effort has been the preparation and submission of a detailed safety report to FANC on the future facility.
- "Obtaining this Nuclear Permit affirms our adherence to the highest nuclear safety standards for our upcoming facility," said Mr. van Put.
Fabry disease,
RMB,
PD,
Drug development,
Strong,
Ohio State University,
RNA,
Insight Partners,
Pharmacology,
American College,
Radiopharmaceutical,
VBI,
Willebrand,
RTW,
Pattern hair loss,
GMP,
Stroke,
Good manufacturing practice,
Therapy,
Skin,
GCS,
Atopic dermatitis,
Safety,
Pharmacokinetics,
Von Willebrand factor,
Investment,
AstraZeneca,
Innovation,
Groundbreaking,
Patient,
ARCH Venture Partners,
Pharmaceutical industry NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs). Recently they announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy. AL01211 is a potent, oral, glucosylceramide synthase (GCS) inhibitor being developed for the treatment of Fabry disease and Type 1 Gaucher disease.
Key Points:
- This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
- Recently, Viva Biotech's portfolio companies have new updates.
- NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs).
- Previously, the company had completed a $5.4 million seed funding round, with investors including Rev1 Ventures, Broadview Ventures, and Viva Biotech.
Retrieved on:
Tuesday, January 30, 2024
Berlin, Germany and Gembloux, Belgium – 23 January 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Full-Life Technologies (Full-Life), a clinical stage, fully integrated global radiotherapeutics company today announced they have entered into an agreement for the supply of Actinium-225 (Ac-225).
Key Points:
- Berlin, Germany and Gembloux, Belgium – 23 January 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Full-Life Technologies (Full-Life), a clinical stage, fully integrated global radiotherapeutics company today announced they have entered into an agreement for the supply of Actinium-225 (Ac-225).
- The agreement provides Full-Life with access to Eckert & Ziegler's high-purity Actinium-225, a radionuclide for use in developing the next generation of therapeutic radiopharmaceuticals.
- “We are delighted to have forged a supply collaboration with Full-Life Technologies, dedicating ourselves to facilitating their journey in clinical development,” said Dr Harald Hasselmann, CEO of Eckert & Ziegler.
- Eckert & Ziegler brings great expertise and more than three decades of experience as a radioisotope specialist in support of our ambitious development initiatives.”
GEMBLOUX, Belgium, Dec. 7, 2023 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the construction of its new Good Manufacturing Practices (GMP) compliant manufacturing facility in Gembloux, Belgium, for radiopharmaceuticals.
Key Points:
- GEMBLOUX, Belgium, Dec. 7, 2023 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the construction of its new Good Manufacturing Practices (GMP) compliant manufacturing facility in Gembloux, Belgium, for radiopharmaceuticals.
- This strategic investment aims to advance Full-Life's end-to-end solution by enhancing its radiopharmaceutical production capabilities at a key logistical hub to ensure the timely supply and delivery to patients worldwide.
- The 4,000 square meter, state-of-the-art facility, which will serve as Full-Life's production hub, integrates sustainable design with automation and digital quality assurance systems.
- The facility, which will sit on 17,000 square meters of land, is specifically tailored to produce a broad spectrum of radiopharmaceuticals.
GEMBLOUX, Belgium, May 3, 2023 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today is pleased to announce that it has closed on an important land purchase in Wallonia, Belgium, and signed a purchase agreement to build a state-of-the-art, manufacturing facility to produce radiopharmaceuticals to Good Manufacturing Practice (GMP) standards.
Key Points:
- GEMBLOUX, Belgium, May 3, 2023 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today is pleased to announce that it has closed on an important land purchase in Wallonia, Belgium, and signed a purchase agreement to build a state-of-the-art, manufacturing facility to produce radiopharmaceuticals to Good Manufacturing Practice (GMP) standards.
- "Production capability and capacity, as well as logistics challenges have been major bottlenecks to radiotherapeutic discovery and development," said Philippe van Put, General Manager of Full-Life Technology Europe.
- "The advanced GMP manufacturing facility we are building at this 17,000 square meter site, will provide us with an internal, integrated manufacturing solution and a strong competitive advantage."
- The region is a leading hub for radiopharmaceutical production, and Full-Life will leverage its expertise and the local ecosystem to accelerate the facility's construction and GMP drug production.
GEMBLOUX, Belgium, May 4, 2023 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today is pleased to announce that it has closed on an important land purchase in Wallonia, Belgium, and signed a purchase agreement to build a state-of-the-art, manufacturing facility to produce radiopharmaceuticals to Good Manufacturing Practice (GMP) standards.
Key Points:
- GEMBLOUX, Belgium, May 4, 2023 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today is pleased to announce that it has closed on an important land purchase in Wallonia, Belgium, and signed a purchase agreement to build a state-of-the-art, manufacturing facility to produce radiopharmaceuticals to Good Manufacturing Practice (GMP) standards.
- "Production capability and capacity, as well as logistics challenges have been major bottlenecks to radiotherapeutic discovery and development," said Philippe van Put, General Manager of Full-Life Technology Europe.
- "The advanced GMP manufacturing facility we are building at this 17,000 square meter site, will provide us with an internal, integrated manufacturing solution and a strong competitive advantage."
- The region is a leading hub for radiopharmaceutical production, and Full-Life will leverage its expertise and the local ecosystem to accelerate the facility's construction and GMP drug production.
Retrieved on:
Tuesday, January 17, 2023
IND,
Radiopharmaceutical,
Oncology,
National Cancer Institute,
Health,
University,
Lymphoma,
Eli Lilly,
Therapy,
Merck Group,
Merck,
Germinal center B-cell like diffuse large B-cell lymphoma,
Science,
Master of Science,
University Hospital Heidelberg,
CD38,
Organic chemistry,
IPO,
MD,
FDA,
Head,
Chinese Academy of Sciences,
NBE,
Novo Nordisk,
Boehringer Ingelheim,
CSO,
CD19,
EGFR,
RDC,
Cancer,
Full Life Christian Centre,
Clinical trial,
German Cancer Research Center,
CMO,
Acquisition,
Doctor of Philosophy,
Anti-CD19 immunotoxin,
S.A,
PSMA,
Pharmaceutical industry,
Lilly,
Chemistry MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).
Key Points:
- MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).
- Dr. Heeger has held senior oncology clinical development positions at both large and emerging companies for more than 15 years.
- "He joins Full-Life as we are accelerating plans for our first targeted radiopharmaceuticals to enter clinical trials.
- Dr. Liu has had a highly successful, 18-year career in therapeutic discovery, including at Eli Lilly and Novo Nordisk.
Retrieved on:
Tuesday, January 17, 2023
IND,
Radiopharmaceutical,
Oncology,
National Cancer Institute,
Health,
University,
Lymphoma,
Eli Lilly,
Therapy,
Merck Group,
Merck,
Germinal center B-cell like diffuse large B-cell lymphoma,
Science,
Master of Science,
University Hospital Heidelberg,
CD38,
Organic chemistry,
IPO,
MD,
FDA,
Head,
Chinese Academy of Sciences,
NBE,
Novo Nordisk,
Boehringer Ingelheim,
CSO,
CD19,
EGFR,
RDC,
Cancer,
Full Life Christian Centre,
Clinical trial,
German Cancer Research Center,
CMO,
Acquisition,
Doctor of Philosophy,
Anti-CD19 immunotoxin,
S.A,
PSMA,
Pharmaceutical industry,
Lilly,
Chemistry MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).
Key Points:
- MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).
- Dr. Heeger has held senior oncology clinical development positions at both large and emerging companies for more than 15 years.
- "He joins Full-Life as we are accelerating plans for our first targeted radiopharmaceuticals to enter clinical trials.
- Dr. Liu has had a highly successful, 18-year career in therapeutic discovery, including at Eli Lilly and Novo Nordisk.
Dai,
Peptide,
Focus X,
Full Life Christian Centre,
CADD,
CMC,
Cryogenic electron microscopy,
PCC,
Radiopharmaceutical,
Trust,
Chemical substance,
IIT,
Therapy,
Cancer,
Research,
ASMS,
CSO,
HDX,
EFS,
Toxicity,
DNA,
Patient,
Acquisition,
Euler's totient function,
SPR,
Head,
Control,
CIO,
Antibody,
Drug,
PDC,
Pharmaceutical industry,
Fine chemical,
Manufacturing They completed their angel round in the third quarter of 2020, which was led by Viva.
Key Points:
- They completed their angel round in the third quarter of 2020, which was led by Viva.
- In addition to financial support, Viva also provided Focus-X with comprehensive incubation services to help it realize the transformation from "concept to product."
- Viva provides efficient and high-quality screening and synthesis services for Focus-X with the help of its peptide research and development platform.
- Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators.
Health,
Manufacturing,
Other Manufacturing,
Radiology,
Pharmaceutical,
Biotechnology,
Radiation,
Therapy,
Strategic planning,
University,
BLA,
Acquisition,
Novartis,
Ovarian cancer,
Director,
Roivant Sciences,
Nuclear energy,
Research,
Full Life Christian Centre,
Patient,
Citibank,
The Universe (Catholic newspaper),
University of Detroit Mercy,
Silicon,
Biochemistry,
Cranial nerve nucleus,
Control,
Wharton School of the University of Pennsylvania,
Abbott,
AREVA,
General manager,
Engineering,
IRE,
ImmunoGen,
CEO,
Philippe,
NASDAQ,
Platinum,
MBA,
FDA,
Institute,
Partner (business rank),
Nuclear technology,
Board,
Safety,
Eli Lilly,
Half-life,
Radiopharmaceutical,
Applied science,
Biotechnology,
Roche,
Wendell Pritchett,
ADC,
Management,
Fine chemical,
Chemistry,
Gordian Full-Life Technologies Co., Ltd. today announced four key appointments to its executive team.
Key Points:
- Full-Life Technologies Co., Ltd. today announced four key appointments to its executive team.
- He noted that the core executive team also includes Full-Life co-founder and Chief Operating Officer Nicholas Wong, Ph.D.
Dr. Chari is an internationally renowned antibody-drug conjugate (ADC) expert .
- Mr. Sun is a seasoned life science executive with more than a decade of experience and strong track record in biotechnology.
- Full-Life Technologies Limited is a fully integrated global Nuclear Health company headquartered in Shanghai with operations in Europe.
